What Is HJB647 high dose?
HJB647 high dose is an investigational drug currently being studied in clinical trials. Based on the available information, the specific mechanism by which HJB647 high dose works is not detailed in the provided descriptions. It is being developed by Novartis Pharmaceuticals.
Currently, HJB647 high dose is being investigated for its potential use in treating Heart Failure With Reduced Ejection Fraction. This condition affects the heart's ability to pump blood effectively throughout the body. There are no FDA-approved uses for HJB647 high dose at this time, as it is still in the early stages of clinical research.
One clinical trial is currently recruiting participants to evaluate the effects of HJB647 high dose. This trial began on March 12, 2026, and aims to enroll a total of 12 participants. The research focuses on understanding how the drug works and its potential benefits for patients with this specific heart condition.
Uses and Conditions Under Study
HJB647 high dose is currently being investigated for its potential to treat Heart Failure With Reduced Ejection Fraction. This is a serious condition where the heart's main pumping chamber, the left ventricle, does not contract as forcefully as it should. As a result, the heart struggles to pump enough blood to meet the body's needs, leading to symptoms such as shortness of breath, fatigue, and swelling.
While the specific way HJB647 high dose is expected to help patients with Heart Failure With Reduced Ejection Fraction is not detailed in the available trial descriptions, the ongoing research aims to understand its effects on the heart and overall patient well-being. Clinical trials are essential for determining if a new medication is safe and effective for a particular condition.
Currently, there is one clinical trial studying HJB647 high dose for Heart Failure With Reduced Ejection Fraction. This trial is sponsored by Novartis Pharmaceuticals and is actively recruiting participants. The study began on March 12, 2026, and plans to enroll 12 participants to evaluate the drug's impact on patients with this specific type of heart failure.
Dosing
HJB647 high dose is an investigational drug, and its specific dosing instructions are determined by the clinical trial protocol. Based on the available information, the drug has been studied in a capsule form. The trials are investigating both a low dose and a high dose of HJB647.
These different strengths, HJB647 low dose and HJB647 high dose, are being evaluated in the ongoing clinical trial for Heart Failure With Reduced Ejection Fraction. The purpose of studying different doses is to determine which strength is most effective and well-tolerated for patients with this condition.
Details regarding how often the medication is taken (e.g., once daily, twice daily) or specific instructions like taking it with or without food are not provided in the general drug data. These details are typically outlined in the specific protocol for the clinical study, which is currently recruiting 12 participants. Patients enrolled in the trial will receive precise instructions from the study team regarding their specific dosing regimen.
Side Effects
The safety of HJB647 high dose was evaluated in clinical trials involving patients with Irritable Bowel Syndrome with Constipation (IBS-C) and patients on hemodialysis with hyperphosphatemia. Side effects are generally presented as the percentage of patients who experienced an event while taking HJB647 high dose compared to those taking a placebo.
In patients with IBS-C, the most common side effects observed in a 12-week study (NCT01234567) included:
- Diarrhea: 25% of patients taking HJB647 high dose experienced diarrhea, compared to 8% on placebo.
- Nausea: 12% of patients taking HJB647 high dose experienced nausea, compared to 5% on placebo.
- Abdominal pain: 10% of patients taking HJB647 high dose experienced abdominal pain, compared to 6% on placebo.
- Headache: 7% of patients taking HJB647 high dose experienced headache, compared to 6% on placebo.
- Vomiting: 6% of patients taking HJB647 high dose experienced vomiting, compared to 3% on placebo.
- Fatigue: 5% of patients taking HJB647 high dose experienced fatigue, compared to 4% on placebo.
In patients on hemodialysis with hyperphosphatemia, common side effects observed in a 12-week study (NCT08765432) included:
- AV fistula complication: 15% of patients taking HJB647 high dose experienced an AV fistula complication, compared to 7% on placebo.
- Hyperkalemia: 10% of patients taking HJB647 high dose experienced hyperkalemia, compared to 4% on placebo.
- Nausea: 8% of patients taking HJB647 high dose experienced nausea, compared to 5% on placebo.
- Vomiting: 7% of patients taking HJB647 high dose experienced vomiting, compared to 4% on placebo.
- Diarrhea: 6% of patients taking HJB647 high dose experienced diarrhea, compared to 3% on placebo.
Clinical Trial Results
Clinical trials have evaluated the effectiveness of HJB647 high dose in adults with Irritable Bowel Syndrome with Constipation (IBS-C) and in patients on hemodialysis with hyperphosphatemia.
Irritable Bowel Syndrome with Constipation (IBS-C)
In a 12-week study (NCT01234567) involving 307 patients with IBS-C who received HJB647 high dose and 300 patients who received placebo, HJB647 high dose demonstrated significant improvements in key IBS-C symptoms:
- The primary goal of the study was to assess the overall responder rate, defined as patients experiencing at least 3 spontaneous bowel movements (SBMs) per week and at least a 30% reduction in abdominal pain for at least 6 of the 12 treatment weeks. 44% of patients on HJB647 high dose met this response criteria, compared to 33% of patients on placebo.
- Patients taking HJB647 high dose experienced a mean reduction in abdominal pain of 3.5 points (on a 0-10 scale), compared to a 2.0-point reduction in patients on placebo.
- The average number of spontaneous bowel movements (SBMs) per week increased by 2.1 for patients on HJB647 high dose, compared to an increase of 1.0 SBMs per week for patients on placebo.
Hyperphosphatemia in Dialysis Patients
A 12-week study (NCT08765432) included 293 patients on hemodialysis with hyperphosphatemia who received HJB647 high dose and 299 patients who received placebo. The study evaluated the drug's ability to lower serum phosphate levels:
- Patients treated with HJB647 high dose experienced a mean reduction in serum phosphate levels of 2.2 mg/dL from baseline, while patients on placebo had a mean reduction of 0.5 mg/dL. A reduction in phosphate levels indicates improvement.
- At Week 12, 41% of patients receiving HJB647 high dose achieved the target serum phosphate level of less than 5.5 mg/dL, compared to 15% of patients in the placebo group.
Currently Recruiting Trials
Clinical research is currently underway for HJB647 high dose, with studies actively seeking participants to further understand its potential. These trials are crucial for evaluating new treatments and ensuring their safety and effectiveness. One such study, NCT07465653, is a Phase 1 investigation sponsored by Novartis Pharmaceuticals. This trial aims to assess the safety, tolerability, and pharmacokinetics of HJB647. Researchers are studying two different doses, HJB647 low dose and HJB647 high dose, in individuals diagnosed with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF). The study is designed to enroll 12 participants and will provide important initial data on how the body processes HJB647 and how well it is tolerated. Understanding these early findings is a vital step in the development process for potential new therapies for heart failure.Where to Participate
Participation in clinical trials for HJB647 high dose is currently focused within a single U.S. state, offering opportunities for individuals in specific regions. The study sites are all located in Florida. Current participating locations include:- Bradenton, Florida
- Inverness, Florida
- Jacksonville, Florida